Hoth Therapeutics, Inc. (HOTH)
HOTH moved a median of -0.04% 30 minutes after news, and 0.00% by the close. How HOTH actually reacts to news — the realized, point-in-time move the market made, measured across 177 labeled events over the last three years with zero look-ahead.
HOTH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 162 |
| 30-min | -0.04% | 41% | 165 |
| 60-min | -0.09% | 39% | 165 |
| to close | 0.00% | 49% | 163 |
| Middle 50% of HOTH reactions | -3.64% to +1.14% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 177 |
Half of all Hoth Therapeutics, Inc. news events land between -3.64% and +1.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when HOTH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HOTH's baseline. Nothing else.
Recent HOTH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Rocket One Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Rocket One Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Rocket One Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Hoth Therapeutics, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -3.04% | +62.78% | |
| Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications | Press release | PR Newswire | -3.04% | +62.78% | |
| Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform | Press release | PR Newswire | +1.13% | +3.86% | |
| Form 8-K Hoth Therapeutics, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.11% | |
| AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomag | Press release | PR Newswire | +2.42% | +10.09% | |
| Form 10-Q Hoth Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.29% | +0.28% | |
| Form 8-K Hoth Therapeutics, Inc. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -4.25% | |
| Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients | Press release | PR Newswire | +1.00% | +5.63% | |
| Form 8-K Hoth Therapeutics, Inc. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +0.78% | |
| Form 8-K Hoth Therapeutics, Inc. For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | +1.83% | |
| Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide | Press release | PR Newswire | +7.03% | -7.73% | |
| Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide | Press release | PR Newswire | +7.03% | -7.73% | |
| Form 8-K Hoth Therapeutics, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +3.49% | +1.58% | |
| Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering | Press release | PR Newswire | +3.49% | +1.58% | |
| Hoth Therapeutics Announces $2.0 Million Registered Direct Offering | Press release | PR Newswire | -19.06% | -23.61% | |
| Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six | Press release | PR Newswire | +1.75% | -35.60% | |
| Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology | Press release | PR Newswire | — | +8.33% | |
| Form 10-K Hoth Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.77% | -2.77% | |
| Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery | Press release | PR Newswire | -1.14% | -4.67% | |
| Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption | Press release | PR Newswire | -1.61% | -4.70% | |
| Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model | Press release | PR Newswire | +2.00% | +0.50% | |
| Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program | Press release | PR Newswire | -1.00% | +4.04% | |
| HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES | Press release | PR Newswire | +0.00% | +1.92% | |
| Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases | Press release | PR Newswire | +1.07% | +5.38% | |
| Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model | Press release | PR Newswire | -2.39% | +10.59% | |
| Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets | Press release | PR Newswire | -2.89% | -3.74% | |
| Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients | Press release | PR Newswire | +2.83% | -0.94% | |
| Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position | Press release | PR Newswire | -1.34% | -6.25% | |
| Form 8-K Hoth Therapeutics, Inc. For: Jan 16 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | -1.89% | |
| Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation | Press release | PR Newswire | -4.54% | -1.82% | |
| Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform | Press release | PR Newswire | +1.95% | +4.90% | |
| Form EFFECT Hoth Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.72% | +2.56% | |
| Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program | Press release | PR Newswire | -0.25% | +1.44% | |
| Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 | Press release | PR Newswire | +0.00% | -5.00% | |
| Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities | Press release | PR Newswire | +0.42% | -14.17% | |
| Form S-3 Hoth Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.17% | -2.50% | |
| Form 10-Q Hoth Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.81% | — | |
| Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease | Press release | PR Newswire | +0.37% | +2.59% | |
| Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers | Press release | PR Newswire | +1.40% | +0.00% | |
| Form 8-K Hoth Therapeutics, Inc. For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.71% | |
| Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform | Press release | PR Newswire | -1.77% | -6.51% | |
| Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025 | Press release | PR Newswire | +0.66% | +1.32% | |
| Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities | Press release | PR Newswire | -0.97% | -5.80% | |
| Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History | Press release | PR Newswire | -2.68% | -0.54% | |
| Form 8-K Hoth Therapeutics, Inc. For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | -7.12% | -4.19% | |
| Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities | Press release | PR Newswire | +1.30% | +11.03% | |
| Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development | Press release | PR Newswire | +0.79% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HOTH section they belong to.
Where else HOTH is measured.
HOTH earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Hoth Therapeutics, Inc.'s median reaction calculated?
Every labeled HOTH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 177 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of HOTH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HOTH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.